Potassium Cation
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Potassium Cation: From Electrolyte Supplementation to Hypertensive Disorder
One-Sentence Summary
Potassium Cation (DrugBank DB01345) is a fundamental electrolyte used for potassium replacement/supplementation; no original indication or product license data is currently on file for this entity. The TxGNN model predicts it may be effective for Hypertensive Disorder, with 3 clinical trials and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the available regulatory dataset (potassium cation is generally used as an electrolyte/potassium replacement agent) |
| Predicted New Indication | Hypertensive Disorder |
| TxGNN Prediction Score | 99.20% |
| Evidence Level | L2 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on known pharmacology, potassium is the principal intracellular cation and, via the Na⁺/K⁺-ATPase pump, regulates vascular smooth muscle tone, suppresses renin secretion, and promotes natriuresis — effects that counteract the pressor response to high sodium intake.
This mechanism is not a novel model hypothesis but is already supported by decades of human dietary and epidemiological evidence: the DASH diet and WHO potassium intake guidelines both rely on this exact pathway to lower blood pressure. The predicted link between potassium supplementation and hypertension is therefore mechanistically well-grounded rather than speculative.
The main caveat is that most supporting evidence concerns dietary potassium rather than the pharmaceutical potassium cation product itself, and the benefit is counterbalanced by a hyperkalemia risk in patients with impaired renal function — a population where potassium is more often contraindicated than therapeutic. This is the central guardrail for this candidate.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06683430 | NA | Completed | 62 | High-potassium, low-sodium diet (3500 mg K⁺/1500 mg Na⁺) in a 14-day RCT for blood pressure reduction in older adults |
| NCT02910427 | NA | Completed | 291 | Potassium/magnesium-enriched salt intervention in stroke patients; blood pressure evaluated as a secondary outcome |
| NCT06256991 | Phase 4 | Recruiting | 44 | Placebo-controlled crossover RCT testing whether potassium correction (patiromer) allows RAAS-blocker up-titration and reduces blood pressure/albuminuria in CKD stage 3b/4 |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27455317 | 2016 | Review (Tier 1) | Nutrients | Reviews potassium intake, bioavailability, and effects on hypertension and glucose control |
| 1986994 | 1991 | Review/Cohort (Tier 1) | Hypertension | Low potassium intake linked to hypertension and stroke risk; potassium increases natriuresis and may blunt sodium’s pressor effect |
| 29492706 | 2018 | Review | Curr Cardiol Rep | Discusses hyperkalemia risk in hypertensive patients, especially with CKD, diabetes, heart failure, or RAAS inhibitor use |
| 24459498 | 2007 | Review | Electrolyte Blood Press | Reviews hypertensive hypokalemic disorders and the aldosterone-mediated renal handling of potassium |
| 34063969 | 2021 | Review (Tier 2) | Nutrients | Potassium promotes sodium excretion with an antihypertensive effect, particularly relevant in CKD management |
| 32498812 | 2020 | Review (Tier 2) | J Am Coll Cardiol | State-of-the-art review on dyskalemia (hypo/hyperkalemia) in heart failure and its prognostic implications |
| 24721891 | 2015 | Review (Tier 2) | Clin J Am Soc Nephrol | Foundational review of renal regulation of potassium homeostasis |
| 39604607 | 2025 | Review (Tier 3) | Heart Fail Rev | Multidisciplinary expert perspective on hyperkalemia management and new potassium binders |
| 15692166 | 2005 | Review | Clin Calcium | Discusses cellular Na:K ratio and its direct/indirect role in blood pressure regulation |
| 27194424 | 2017 | Review (Tier 3) | Pediatr Nephrol | Reviews physiological consequences of deviations in serum potassium, “friend or foe” framing |
US Market Information
No marketing authorizations are on file for this entity (total_licenses = 0, market status: Not Marketed). This may reflect a data gap in the regulatory dataset rather than true absence of potassium products in the US market, since potassium salts are widely marketed generically under various formulations.
Safety Considerations
Please refer to the package insert for safety information. No structured warnings, contraindications, or DDI data are currently available for this entity (flagged as a Blocking data gap, DG001).
Guardrail note from evidence review: Multiple retrieved publications emphasize that hyperkalemia risk rises sharply in patients with chronic kidney disease, diabetes, heart failure, or those on RAAS-inhibitor therapy — the same populations where hypertension is most prevalent. Any repurposing pathway must screen for renal function and concurrent RAAS-inhibitor use.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic link between potassium and blood pressure reduction is well-established (DASH diet, WHO guidance) and supported by one completed dietary RCT (n=62) and an ongoing Phase 4 RCT in CKD patients. However, evidence targets dietary potassium intake rather than the pharmaceutical potassium cation product specifically, and the population most likely to benefit overlaps substantially with the population most at risk of hyperkalemia.
To proceed, the following is needed:
- TFDA/FDA label warnings and contraindications (Blocking data gap, DG001) — required before any S1 safety review
- Confirmed mechanism of action data via DrugBank (High-severity data gap, DG002)
- A trial or evidence source testing the pharmaceutical potassium cation product (not dietary intervention) specifically for blood pressure outcomes
- Renal function-based screening protocol to exclude hyperkalemia-risk patients (CKD, RAAS-inhibitor users, diabetics)
- US/Taiwan regulatory licensing status confirmation, given the current “Not Marketed” record
Other predicted indications (pulmonary hypertension variants, malignant hypertensive/renovascular renal disease, Braddock syndrome) are rated Hold — they carry TxGNN scores in a similar range but lack supporting clinical trials or mechanistically relevant literature, and in some cases (malignant hypertensive renal disease) potassium supplementation is more plausibly contraindicated than therapeutic.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.